Experimental immune therapy aims to reduce deaths in severe pneumonia
Disease control
Recruiting now
This study tests whether a single dose of an experimental immune cell therapy called agenT-797, given alongside standard care, can lower the risk of death in adults with severe pneumonia and breathing failure. About 90 people in intensive care will receive either agenT-797 or a p…
Phase: PHASE2 • Sponsor: MiNK Therapeutics • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC